ANALYSIS OF MONOCYTES SUBPOPULATIONS WITH CYTODIFF?* IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
(Abstract release date: 05/21/15)
EHA Library. Sukhacheva E. 06/12/15; 102815; PB1711
Disclosure(s): Beckman Coulter Eurocenter
Elena Sukhacheva
Contributions
Contributions
Abstract
Abstract: PB1711
Type: Publication Only
Background
During last decade 3 sub-populations of monocytes have been described in the human blood: classical, intermediate and non-classical monocytes, which can be differentiated with flow cytometry based on the expression of CD14 and CD16. The involvement of monocyte subpopulations in different pathological processes also was described, including sepsis, HIV infection, tuberculosis and cardiovascular disorders. Very limited information available about monocyte sub-populations in Chronic Lymphocytic Leukemia (CLL), but according to literature they seem to be important for tumor progression and immune suppression in CLL.
Aims
The aim of our study was to compare CD-16 negative and CD16-positive monocytes in CLL patients and in normal individuals. Also we aimed to compare the groups of CLL patients with bad and good prognosis.
Methods
58 patients with confirmed diagnosis of CLL were included in the study at the time of diagnosis. The comparison group included 307 blood donors. EDTA-anticoagulated blood sample were analyzed with CytoDiff™* panel according to the recommendation of the supplier. The CytoDiff™* panel is a 5-color / 6-marker reagent that provides an extended 18-part white blood cell differential from whole blood specimens by flow cytometry (Beckman Coulter). Among other WBC sub-populations, CytoDiff™* is able to provide the count of CD16-positive and CD16-negative monocytes (@M+ and @M-) in peripheral blood. The expression of CD38 on lymphocytes was used as prognostic marker for CLL patients.
Results
The absolute number of classical CD16-negative monocytes (@M-) was similar in donors and in CLL patients (503 cells/mcl vs 510 cells/mcl respectively). When compared to normal individuals, patients with CLL were characterized by higher absolute count of CD16-positive monocytes (@M-, 40 cells/mcl vs 30 cells/mcl, p=0.0007), higher proportion of CD16-positive monocytes among all monocytes (@M+/Total Mono; 8.8% vs 5.8%, p<0.0001) and lower proportion of CD16-negative monocytes among all monocytes ((@M-/Total Mono; 94.2% vs 91.3%, p<0.0001).
Summary
CytoDiff™* analysis is very efficient tool to monitor the monocyte subpopulations in various pathologies, including CLL. The exact role of CD16-positive monocytes in CLL and their significance remain to be investigated on a larger cohort of patients.
Keyword(s): Chronic lymphocytic leukemia, Flow cytometry, Monocyte
Session topic: Publication Only
Type: Publication Only
Background
During last decade 3 sub-populations of monocytes have been described in the human blood: classical, intermediate and non-classical monocytes, which can be differentiated with flow cytometry based on the expression of CD14 and CD16. The involvement of monocyte subpopulations in different pathological processes also was described, including sepsis, HIV infection, tuberculosis and cardiovascular disorders. Very limited information available about monocyte sub-populations in Chronic Lymphocytic Leukemia (CLL), but according to literature they seem to be important for tumor progression and immune suppression in CLL.
Aims
The aim of our study was to compare CD-16 negative and CD16-positive monocytes in CLL patients and in normal individuals. Also we aimed to compare the groups of CLL patients with bad and good prognosis.
Methods
58 patients with confirmed diagnosis of CLL were included in the study at the time of diagnosis. The comparison group included 307 blood donors. EDTA-anticoagulated blood sample were analyzed with CytoDiff™* panel according to the recommendation of the supplier. The CytoDiff™* panel is a 5-color / 6-marker reagent that provides an extended 18-part white blood cell differential from whole blood specimens by flow cytometry (Beckman Coulter). Among other WBC sub-populations, CytoDiff™* is able to provide the count of CD16-positive and CD16-negative monocytes (@M+ and @M-) in peripheral blood. The expression of CD38 on lymphocytes was used as prognostic marker for CLL patients.
Results
The absolute number of classical CD16-negative monocytes (@M-) was similar in donors and in CLL patients (503 cells/mcl vs 510 cells/mcl respectively). When compared to normal individuals, patients with CLL were characterized by higher absolute count of CD16-positive monocytes (@M-, 40 cells/mcl vs 30 cells/mcl, p=0.0007), higher proportion of CD16-positive monocytes among all monocytes (@M+/Total Mono; 8.8% vs 5.8%, p<0.0001) and lower proportion of CD16-negative monocytes among all monocytes ((@M-/Total Mono; 94.2% vs 91.3%, p<0.0001).
Within the group of 58 CLL patients we identified patients with unfavorable prognosis (n=16) based on the CD38 expression (>6%). In patients with bad prognosis CytoDiff™* results revealed higher proportional (0.24% vs 0.175%, p=0.1346) and absolute (63 cells/mcl vs 38 cells/mcl, p=0.166) count of CD16-positive monocytes, but the difference did not reach the statistical significance.
Summary
CytoDiff™* analysis is very efficient tool to monitor the monocyte subpopulations in various pathologies, including CLL. The exact role of CD16-positive monocytes in CLL and their significance remain to be investigated on a larger cohort of patients.
*Not available in the United States and other geographies.
For research use only. Not for use in diagnostic procedures.
@ - Research Use Only (RUO) parameters
Keyword(s): Chronic lymphocytic leukemia, Flow cytometry, Monocyte
Session topic: Publication Only
Abstract: PB1711
Type: Publication Only
Background
During last decade 3 sub-populations of monocytes have been described in the human blood: classical, intermediate and non-classical monocytes, which can be differentiated with flow cytometry based on the expression of CD14 and CD16. The involvement of monocyte subpopulations in different pathological processes also was described, including sepsis, HIV infection, tuberculosis and cardiovascular disorders. Very limited information available about monocyte sub-populations in Chronic Lymphocytic Leukemia (CLL), but according to literature they seem to be important for tumor progression and immune suppression in CLL.
Aims
The aim of our study was to compare CD-16 negative and CD16-positive monocytes in CLL patients and in normal individuals. Also we aimed to compare the groups of CLL patients with bad and good prognosis.
Methods
58 patients with confirmed diagnosis of CLL were included in the study at the time of diagnosis. The comparison group included 307 blood donors. EDTA-anticoagulated blood sample were analyzed with CytoDiff™* panel according to the recommendation of the supplier. The CytoDiff™* panel is a 5-color / 6-marker reagent that provides an extended 18-part white blood cell differential from whole blood specimens by flow cytometry (Beckman Coulter). Among other WBC sub-populations, CytoDiff™* is able to provide the count of CD16-positive and CD16-negative monocytes (@M+ and @M-) in peripheral blood. The expression of CD38 on lymphocytes was used as prognostic marker for CLL patients.
Results
The absolute number of classical CD16-negative monocytes (@M-) was similar in donors and in CLL patients (503 cells/mcl vs 510 cells/mcl respectively). When compared to normal individuals, patients with CLL were characterized by higher absolute count of CD16-positive monocytes (@M-, 40 cells/mcl vs 30 cells/mcl, p=0.0007), higher proportion of CD16-positive monocytes among all monocytes (@M+/Total Mono; 8.8% vs 5.8%, p<0.0001) and lower proportion of CD16-negative monocytes among all monocytes ((@M-/Total Mono; 94.2% vs 91.3%, p<0.0001).
Summary
CytoDiff™* analysis is very efficient tool to monitor the monocyte subpopulations in various pathologies, including CLL. The exact role of CD16-positive monocytes in CLL and their significance remain to be investigated on a larger cohort of patients.
Keyword(s): Chronic lymphocytic leukemia, Flow cytometry, Monocyte
Session topic: Publication Only
Type: Publication Only
Background
During last decade 3 sub-populations of monocytes have been described in the human blood: classical, intermediate and non-classical monocytes, which can be differentiated with flow cytometry based on the expression of CD14 and CD16. The involvement of monocyte subpopulations in different pathological processes also was described, including sepsis, HIV infection, tuberculosis and cardiovascular disorders. Very limited information available about monocyte sub-populations in Chronic Lymphocytic Leukemia (CLL), but according to literature they seem to be important for tumor progression and immune suppression in CLL.
Aims
The aim of our study was to compare CD-16 negative and CD16-positive monocytes in CLL patients and in normal individuals. Also we aimed to compare the groups of CLL patients with bad and good prognosis.
Methods
58 patients with confirmed diagnosis of CLL were included in the study at the time of diagnosis. The comparison group included 307 blood donors. EDTA-anticoagulated blood sample were analyzed with CytoDiff™* panel according to the recommendation of the supplier. The CytoDiff™* panel is a 5-color / 6-marker reagent that provides an extended 18-part white blood cell differential from whole blood specimens by flow cytometry (Beckman Coulter). Among other WBC sub-populations, CytoDiff™* is able to provide the count of CD16-positive and CD16-negative monocytes (@M+ and @M-) in peripheral blood. The expression of CD38 on lymphocytes was used as prognostic marker for CLL patients.
Results
The absolute number of classical CD16-negative monocytes (@M-) was similar in donors and in CLL patients (503 cells/mcl vs 510 cells/mcl respectively). When compared to normal individuals, patients with CLL were characterized by higher absolute count of CD16-positive monocytes (@M-, 40 cells/mcl vs 30 cells/mcl, p=0.0007), higher proportion of CD16-positive monocytes among all monocytes (@M+/Total Mono; 8.8% vs 5.8%, p<0.0001) and lower proportion of CD16-negative monocytes among all monocytes ((@M-/Total Mono; 94.2% vs 91.3%, p<0.0001).
Within the group of 58 CLL patients we identified patients with unfavorable prognosis (n=16) based on the CD38 expression (>6%). In patients with bad prognosis CytoDiff™* results revealed higher proportional (0.24% vs 0.175%, p=0.1346) and absolute (63 cells/mcl vs 38 cells/mcl, p=0.166) count of CD16-positive monocytes, but the difference did not reach the statistical significance.
Summary
CytoDiff™* analysis is very efficient tool to monitor the monocyte subpopulations in various pathologies, including CLL. The exact role of CD16-positive monocytes in CLL and their significance remain to be investigated on a larger cohort of patients.
*Not available in the United States and other geographies.
For research use only. Not for use in diagnostic procedures.
@ - Research Use Only (RUO) parameters
Keyword(s): Chronic lymphocytic leukemia, Flow cytometry, Monocyte
Session topic: Publication Only
{{ help_message }}
{{filter}}